Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: A systematic review and meta-analysis

Oncotarget

Volumn 8, Issue 20, 2017, Pages 33922-33932

  Fan, Gaowei ^a,b   Zhang, Kuo ^a   Ding, Jiansheng ^a   Li, Jinming ^a  

^a BEIJING HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

EGFR; KRAS; Meta analysis; NSCLC; Prognosis

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN; PERTUZUMAB; PROTEIN CTDNA; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; CIRCULATING TUMOR DNA; RAS PROTEIN;

ADVANCED CANCER; CANCER PATIENT; CANCER PROGNOSIS; EXON; HUMAN; META ANALYSIS (TOPIC); MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POPULATION RESEARCH; PROGRESSION FREE SURVIVAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW (TOPIC); FEMALE; GENETICS; LUNG TUMOR; META ANALYSIS; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

CARCINOMA, NON-SMALL-CELL LUNG; CIRCULATING TUMOR DNA; ERBB RECEPTORS; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RAS PROTEINS;

EID: 85019204368     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15412     Document Type: Review

References (33)

1. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304:1497-1500
2. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. The lancet oncology. 2011; 12:175-180
3. Nygaard AD, Spindler KLG, Pallisgaard N, Andersen RF, Jakobsen A. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer. 2013; 79:312-317
4. Chen JY, Cheng YN, Han L, Wei F, Yu WW, Zhang XW, Cao S, Yu JP. Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFRTKIs: a systemic review and meta-analysis. Cancer biology & medicine. 2015; 12:126
5. Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Léna H, Ouafik LH, Besse B, Rouquette I,Westeel V. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). The Lancet. 2016; 387:1415-1426
6. Camps C, Sirera R, Bremnes R, Blasco A, Sancho E, Bayo P, Safont MJ, Sánchez JJ, Tarón M, Rosell R. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung cancer. 2005; 50:339-346
7. Huang Q, Li J, Sun Y, Wang R, Cheng X, Chen H. Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small cell lung cancer by a meta-analysis. CHEST Journal. 2016; 149:1384-1392
8. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JCM, Zaatar A, Sanchez JAO. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. Journal of the National Cancer Institute. 2013:djt072
9. Kuan FC, Kuo LT, Chen MC, Yang CT, Shi CS, Teng D, Lee KD. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. British journal of cancer. 2015
10. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA. Circulating mutant DNA to assess tumor dynamics. Nature medicine. 2008; 14:985-990
11. Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. Journal of Clinical Oncology. 2014; 32:579-586
12. Siravegna G, Bardelli A. Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. Molecular Oncology. 2016; 10:475-480
13. Mao C, Yuan JQ, Yang ZY, Fu XH, Wu XY, Tang JL. Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis. Medicine. 2015; 94
14. Jo P, Jung K, Grade M, Conradi LC, Wolff HA, Kitz J, Becker H, Rüschoff J, Hartmann A, Beissbarth T. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. Surgery. 2012; 151:564-570
15. Xu F, Wu J, Xue C, Zhao Y, Jiang W, Lin L, Wu X, Lu Y, Bai H, Xu J. Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets Ther. 2012; 5:439-447
16. Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clinical Cancer Research. 2012; 18:2391-2401
17. Huang Z, Wang Z, Bai H, Wu M, An T, Zhao J, Yang L, Duan J, Zhuo M, Wang Y. The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thoracic Cancer. 2012; 3:334-340
18. Qin L, Zhong W, Zhang L, Li Ly, Wang Mz. Comparison of three methods for detecting epidermal growth factor receptor mutations in plasma DNA samples of Chinese patients with advanced non-small cell lung cancer. Chinese Medical Journal-Beijing. 2011; 124:887
19. Mack PC, Holland WS, Burich RA, Sangha R, Solis LJ, Li Y, Beckett LA, Lara PN, Davies AM, Gandara DR. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. Journal of Thoracic Oncology. 2009; 4:1466-1472
20. He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N, Xu J. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. International Journal of Cancer. 2009; 125:2393-2399
21. Bai H, Mao L, Zhao J, Yang L, Wang X, Wang J. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. Journal of Clinical Oncology. 2009; 27:2653-2659
22. Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, Koizumi F, Nishio K, Miyamoto K, Fujimura M. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). British journal of cancer. 2007; 97:778-784
23. Zhuo M, Wu M, Zhao J, Song SW, Bai H, Wang S, Yang L, An T, Wang X, Duan J. Epidermal growth factor receptor genotype in plasma DNA and outcome of chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Chinese medical journal. 2011; 124:3510-3514
24. Camps C, Jantus-Lewintre E, Cabrera A, Blasco A, Sanmartín E, Gallach S, Caballero C, del Pozo N, Rosell R, Guijarro R. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer. 2011; 72:365-369
25. Kim ST, Sung JS, Jo UH, Park KH, Shin SW, Kim YH. Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? Medical Oncology. 2013; 30:1-10
26. Ramirez JL, Sarries C, de Castro PL, Roig B, Queralt C, Escuin D, de Aguirre I, Sanchez JM, Manzano JL, Margeli M. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer letters. 2003; 193:207-216
27. Do H, Dobrovic A. Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clinical chemistry. 2015; 61:64-71
28. Tursz T and Bernards R. Hurdles on the road to personalized medicine. Molecular oncology. 2015; 9:935-939
29. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nature reviews Clinical oncology. 2013; 10:472-484
30. Zhai Z, Yu X, Yang B, Zhang Y, Zhang L, Li X, Sun H. (2016). Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. Seminars in Cell & Developmental Biology. 2016
31. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nature Reviews Cancer. 2007; 7:778-790
32. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions 4.2. 5 [updated May 2005]. The cochrane library. 2005
33. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in medicine. 1998; 17:2815-2834